(Q45181392)

English

Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

scientific article published in January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

gynecologic oncology

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

author name string

Russell J Schilder

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

John Blessing

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

language of work or name

0 references

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

96

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

103-107

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Advanced breast cancer: a phase II trial with gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Does adenocarcinoma of uterine cervix have a worse prognosis than squamous carcinoma when treated by radiotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Gemcitabine Is Ineffective in Recurrent, Preirradiated Cervical Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

A phase II trial of gallium nitrate (NSC #15200) in nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.027

7 January 2021

Identifiers

10.1016/J.YGYNO.2004.09.027

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45181392&oldid=2126788339"